RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 In Real-World Settings, EVE and EXE Extend PFS in Breast Cancer: BRAWO
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 36
SP 22
OP 22
DO 10.1177/155989771436018
UL http://mdc.sagepub.com/content/14/36/22.abstract
AB Administration of everolimus (combined with exemestane in real-world conditions extends progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer. Data from the German Breast Cancer Treatment With Afinitor (Everolimus) and Exemestane for ER+ Women trial [BRAWO] are discussed in this article.